The quarter came in materially ahead of the standing revenue expectation. Revenue reached $435.4 million, above the published consensus of roughly $414 million and above the prior $405-$425 million company range; EPS of $0.06 was broadly near, though slightly below, one published $0.07 estimate.
| Metric | Q2 2026 | Q2 2025 | Comparison / expectation |
|---|---|---|---|
| Revenue | $435.4M | $345.3M | +26%; consensus ~ $414.4M |
| Center Margin | $153.0M | $108.4M | +41%; margin rose to 35.2% |
| Adjusted EBITDA | $66.0M | $34.0M | +94%; margin rose to 15.2% |
| Net income | $23.6M | $(3.8)M | Turned profitable |
| Operating cash flow | $99.9M | $64.4M | Q2 cash generation |
| Free cash flow | $87.9M | $56.6M | Q2 cash generation |
The more important beat was operating leverage, not just top-line growth. Visits grew 19% and clinicians 11%, while revenue per visit increased to $166.6 from $157.0, helping Center Margin expand to 35.2% of revenue and Adjusted EBITDA margin to 15.2% from 9.8% a year earlier. The margin improvement suggests the growth is converting into profit faster than the market had assumed. (Q2 2026 Highlights; Quarterly Trends; Quarterly Visits and Total Revenue Per Visit)
Management raised all major full-year targets, reinforcing that the upside was not confined to one quarter. Revenue guidance increased to $1.685-$1.725 billion from $1.640-$1.680 billion, Center Margin to $570-$594 million from $547-$571 million, and Adjusted EBITDA to $215-$235 million from $200-$220 million. The new midpoint implies roughly $15 million more full-year Adjusted EBITDA than the prior midpoint, a meaningful increase relative to the existing plan. (2026 Guidance)
Cash generation is strong, but the buyback headline is less new than it sounds. LifeStance generated $133.0 million of operating cash flow in the first half and repurchased $97.6 million of stock during that period, while cash ended at $225.9 million and net long-term debt at $259.0 million. The newly announced $100 million authorization replaces an existing $100 million authorization approved in February, so it is a continuation of capital deployment rather than an incremental expansion. (Statements of Cash Flows; Balance Sheet, Cash Flow, and Capital Allocation; Item 8.01)
Net read: clearly better than expected, led by revenue quality and margin acceleration. The modest EPS comparison and unchanged size of the repurchase authorization do not offset the revenue beat, sharply higher profitability, strong free cash flow, and broad guidance increase. The main question left for investors is whether the unusually strong margin progression can persist while LifeStance continues opening centers and adding clinicians. (Financial Highlights; 2026 Guidance)
Read the original 8-K on SEC EDGAR ↗